Table 4.
Best Response | No. (%) |
---|---|
Complete response | 31 (15.6%) |
Partial response | 57 (28.6%) |
Total responders | 88 (44.2%) |
Stable disease | 57 (28.6%) |
Disease progression | 5 (2.5%) |
Total non-responders | 62 (31.2%) |
Not evaluable a | 49 (24.6%) |
a Including 11 patients with hematological improvement and 38 patients considered “not evaluable” by clinicians (31 of them had undergone less than 4 therapy cycles).